Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 4/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924384 | 0.94 | PNP (0.41) | HPRT1TLR7CYP3A4CYP2D6PNP | |
| SCHEMBL3996500 | 0.86 | HPRT1 (0.45) | HPRT1TLR7CYP3A4CYP2D6FGFR1 | |
| SCHEMBL4095261 | 0.82 | FGFR1 (0.37) | TLR7CYP3A4CYP2D6FGFR1ADORA2A | |
| SCHEMBL3930482 | 0.82 | TLR7 (0.42) | HPRT1TLR7ADORA2AADORA2B | |
| SCHEMBL4104451 | 0.80 | CYP3A4 (0.41) | TLR7CYP3A4CYP2D6 | |
| SCHEMBL4096883 | 0.80 | PNP (0.41) | HPRT1TLR7PNPFGFR1SLC22A6 | |
| SCHEMBL4100830 | 0.80 | SERPINA3 (0.43) | HPRT1TLR7ADORA2AADORA2B | |
| SCHEMBL4103648 | 0.79 | CYP3A4 (0.41) | HPRT1TLR7CYP3A4CYP2D6 | |
| SCHEMBL4102688 | 0.79 | TLR7 (0.41) | TLR7ADORA2AADORA2B | |
| SCHEMBL4007149 | 0.77 | FGFR1 (0.46) | HPRT1TLR7CYP3A4FGFR1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038290-B1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8338593-B2 | Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008682-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | HPRT1 4194/4885TLR7 1/4885CYP3A4 4601/4885 |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | HPRT1 4030/4885TLR7 1/4885CYP3A4 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.